Radio 5 (RNE) has reported on the “Spark” project, launched by the public-private consortium led by Iproteos, an IRB Barcelona and UB spin-off. IRB Barcelona, CRG, the University of the Basque Country, and the biopharmaceutical company Ascil-Biopharma are also involved in the project. The program includes statements by Javier Meana, researcher at the University of the Basque Country, and Teresa Tarragó, researcher at IRB Barcelona and co-founder of Iproteos.
Listen to the news on Radio 5 (04:30 minutes, in Spanish)
Radio Euskadi interviews Meritxell Teixidó, associate researcher in the Peptide and Protein Laboratory at IRB Barcelona, about the development of a shuttle peptide capable of crossing the blood-brain barrier and carrying therapeutic molecules in to this organ to treat diseases of the central nervous system. In the interview, Teixidó talks about how the shuttle works and about its potential therapeutic applications.
Listen to the interview on Radio Euskadi (10:36 minutes, in Spanish)
Wide coverage in the media about a breakthrough by Ernest Giralt’s group that was presented yesterday in Angewandte Chemie. Specifically, this group has developed and patented a peptide shuttle able to transport substances to the brain. This shuttle has the capacity to cross the blood-brain barrier, a natural defence structure that prevents substances from passing into the brain, thus protecting it against infection. However, this barrier is also a severe obstacle for therapeutics as 98% of promising drugs for the treatment of central nervous system cannot cross it. “Many companies could recover promising molecules that were once discarded and attach them to our shuttles,” comment the...
Chemists at IRB Barcelona patent and present a shuttle capable of transporting molecules into the brain; this achievement could facilitate the treatment of diseases with no therapy available.
98% of drugs targeting the central nervous system are discarded because they are unable to cross the physical barrier that protects the brain.
The IRB Barcelona scientists, together with clinical teams, are now evaluating the potential of their shuttle for rare and orphan diseases.
Various new bulletins on RAC1 radio have included statements by Ernest Giralt, group leader of the Peptide and Protein Laboratory at IRB Barcelona, following the publication of an article on the compound created by his lab that is capable of transporting drugs in to the brain.
The Council recognizes the impact of his research in peptide chemistry with applications in innovative therapies for cancer
The "Ciutat de Barcelona" prize represents the highest recognition that gives the city to its citizens
SmartQuimic has interviewed Teresa Tarragó and Ernest Giralt, IRB Barcelona researchers and co-founders of the spin-off Iproteos, granted the EXPOQUIMIA ’14 award for the creation of IRP19, a new drug for treating cognitive deficits associated with schizophrenia.
Read the interview in SmartQuimic
“La Vanguardia”, together with other national and international media outlets, has published a news story about “Spark”, a project launched by a public-private consortium led by Iproteos, an IRB Barcelona and UB spin-off located at PCB. IRB Barcelona, CRG, the University of the Bask Country, and the biopharmaceutical company Ascil-Biopharma are also involved in the project.
The aim of Spark is to carry out the first preclinical stage of the development of a first-in-class drug to prevent, stop and reverse the progression of cognitive impairment associated with schizophrenia.
The Wall Street International Magazine has published in an article on the development of compounds with therapeutic purposes capable of crossing the blood-brain barrier, which protects the brain from infection. The article highlights recent projects led by Ernest Giralt, group leader of the Peptide and Protein Laboratory at IRB Barcelona and co-founder of the spin-off Iproteos, and includes many statements from the researcher.
Read the article in the Wall Street International Magazine (in Spanish)
The goal of «Spark» is to carry out the first preclinical stage of the development of a first-in-class drug that will prevent, stop and reverse the progression of cognitive impairment associated with schizophrenia and other mental disorders, and to be able to start first-in-humans trials by 2016
The project, which has just won a 500,000 euro endorsement from the Ministry of Economy and Finance and FEDER funds through the “Retos-Colaboración” (Challenges-Collaboration) subprogram- will be developed by a consortium led by the biotech Iproteos -located at the Parc Cientific de Barcelona- and comprised by the company Ascil-Biopharm, IRB Barcelona, the Centre for Genomic Regulation and the University of the Basque Country
Currently there is no drug targetting the cognitive impairment associated with schizophrenia, the third most disabling disease even above paraplegia and blindness- according to the WHO and that affects about 24 million people worldwide. It is also the fifth disease with a higher annual cost to society, with more than 35,000 million euros cost only in the Europe Union